194 related articles for article (PubMed ID: 29747940)
1. Insights into the role of IL-32 in cancer.
Sloot YJE; Smit JW; Joosten LAB; Netea-Maier RT
Semin Immunol; 2018 Aug; 38():24-32. PubMed ID: 29747940
[TBL] [Abstract][Full Text] [Related]
2. Alternatively spliced isoforms of IL-32 differentially influence cell death pathways in cancer cell lines.
Heinhuis B; Plantinga TS; Semango G; Küsters B; Netea MG; Dinarello CA; Smit JWA; Netea-Maier RT; Joosten LAB
Carcinogenesis; 2016 Feb; 37(2):197-205. PubMed ID: 26678222
[TBL] [Abstract][Full Text] [Related]
3. Interleukin 32, inflammation and cancer.
Hong JT; Son DJ; Lee CK; Yoon DY; Lee DH; Park MH
Pharmacol Ther; 2017 Jun; 174():127-137. PubMed ID: 28223235
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-32 monoclonal antibodies for immunohistochemistry, Western blotting, and ELISA.
Kim KH; Shim JH; Seo EH; Cho MC; Kang JW; Kim SH; Yu DY; Song EY; Lee HG; Sohn JH; Kim J; Dinarello CA; Yoon DY
J Immunol Methods; 2008 Apr; 333(1-2):38-50. PubMed ID: 18252253
[TBL] [Abstract][Full Text] [Related]
5. Interplay between thyroid cancer cells and macrophages: effects on IL-32 mediated cell death and thyroid cancer cell migration.
Sloot YJE; Rabold K; Ulas T; De Graaf DM; Heinhuis B; Händler K; Schultze JL; Netea MG; Smit JWA; Joosten LAB; Netea-Maier RT
Cell Oncol (Dordr); 2019 Oct; 42(5):691-703. PubMed ID: 31201646
[TBL] [Abstract][Full Text] [Related]
6. The role of the IL-22/IL-22R1 axis in cancer.
Lim C; Savan R
Cytokine Growth Factor Rev; 2014 Jun; 25(3):257-71. PubMed ID: 24856143
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-32 increases human gastric cancer cell invasion associated with tumor progression and metastasis.
Tsai CY; Wang CS; Tsai MM; Chi HC; Cheng WL; Tseng YH; Chen CY; Lin CD; Wu JI; Wang LH; Lin KH
Clin Cancer Res; 2014 May; 20(9):2276-88. PubMed ID: 24602839
[TBL] [Abstract][Full Text] [Related]
8. Targeting interleukin-22 for cancer therapy.
Markota A; Endres S; Kobold S
Hum Vaccin Immunother; 2018; 14(8):2012-2015. PubMed ID: 29617184
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-33 acts as a pro-inflammatory cytokine and modulates its receptor gene expression in highly metastatic human pancreatic carcinoma cells.
Schmieder A; Multhoff G; Radons J
Cytokine; 2012 Nov; 60(2):514-21. PubMed ID: 22819319
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-32: An endogenous danger signal or master regulator of intracellular pathogen infections-Focus on leishmaniases.
Dos Santos JC; Damen MSMA; Joosten LAB; Ribeiro-Dias F
Semin Immunol; 2018 Aug; 38():15-23. PubMed ID: 29551246
[TBL] [Abstract][Full Text] [Related]
11. Allele-specific long-distance regulation dictates IL-32 isoform switching and mediates susceptibility to HIV-1.
Palstra RJ; de Crignis E; Röling MD; van Staveren T; Kan TW; van Ijcken W; Mueller YM; Katsikis PD; Mahmoudi T
Sci Adv; 2018 Feb; 4(2):e1701729. PubMed ID: 29507875
[TBL] [Abstract][Full Text] [Related]
12. Exploring the Role of IL-32 in HIV-Related Kaposi Sarcoma.
Semango G; Heinhuis B; Plantinga TS; Blokx WAM; Kibiki G; Sonda T; Mavura D; Masenga EJ; Nyindo M; van der Ven AJAM; Joosten LAB
Am J Pathol; 2018 Jan; 188(1):196-203. PubMed ID: 29037857
[TBL] [Abstract][Full Text] [Related]
13. IL-35 induces N2 phenotype of neutrophils to promote tumor growth.
Zou JM; Qin J; Li YC; Wang Y; Li D; Shu Y; Luo C; Wang SS; Chi G; Guo F; Zhang GM; Feng ZH
Oncotarget; 2017 May; 8(20):33501-33514. PubMed ID: 28432279
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-32 gamma specific monoclonal antibody and developing IL-32 specific ELISA.
Lee S; Kim S; Bae S; Choi J; Hong J; Ryoo S; Jhun H; Hong K; Kim E; Jo S; Her E; Kim S
Hybridoma (Larchmt); 2010 Dec; 29(6):501-9. PubMed ID: 21087097
[TBL] [Abstract][Full Text] [Related]
15. IL-32: a host proinflammatory factor against influenza viral replication is upregulated by aberrant epigenetic modifications during influenza A virus infection.
Li W; Sun W; Liu L; Yang F; Li Y; Chen Y; Fang J; Zhang W; Wu J; Zhu Y
J Immunol; 2010 Nov; 185(9):5056-65. PubMed ID: 20889550
[TBL] [Abstract][Full Text] [Related]
16. Interleukins (ILs), a fascinating family of cytokines. Part I: ILs from IL-1 to IL-19.
Fietta P; Costa E; Delsante G
Theor Biol Forum; 2014; 107(1-2):13-45. PubMed ID: 25936211
[TBL] [Abstract][Full Text] [Related]
17. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer.
Taniguchi K; Karin M
Semin Immunol; 2014 Feb; 26(1):54-74. PubMed ID: 24552665
[TBL] [Abstract][Full Text] [Related]
18. Novel insights into the biology of interleukin-32.
Joosten LA; Heinhuis B; Netea MG; Dinarello CA
Cell Mol Life Sci; 2013 Oct; 70(20):3883-92. PubMed ID: 23463238
[TBL] [Abstract][Full Text] [Related]
19. IL-32γ enhances TNF-α-induced cell death in colon cancer.
Park ES; Yoo JM; Yoo HS; Yoon DY; Yun YP; Hong J
Mol Carcinog; 2014 Feb; 53 Suppl 1():E23-35. PubMed ID: 23255489
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of the IL-33/ST2 network in the progression of human colorectal adenoma to sporadic colorectal cancer.
Cui G; Qi H; Gundersen MD; Yang H; Christiansen I; Sørbye SW; Goll R; Florholmen J
Cancer Immunol Immunother; 2015 Feb; 64(2):181-90. PubMed ID: 25324197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
